A US advisory committee endorsed a significant expansion of the population recommended to receive Merck & Co. Inc.’s human papilloma virus vaccine Gardasil 9 but attached an important caveat – vaccination is justified only for high-risk individuals, who likely represent a fraction of this broader group.
The question remains, however, how individuals at high risk of contracting the sexually transmitted virus will be identified.







